n=171 | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|
Hazard ratio (95%CI) | P value | Hazard ratio (95%CI) | P value | ||
Age (year) (66≦/≧67) | (83/88) | 1.54 (0.79-3.02) | 0.19 | ||
Gender (male/female) | (99/72) | 1.17 (0.60-2.28) | 0.63 | ||
Histological grade (G3,4/G1,2) | (18/153) | 0.78 (0. 27-2.15) | 0.78 | ||
Tumor volume (≧6335/6335<) | (82/89) | 1.05 (0.54-2.05) | 0.86 | ||
pT3,4/pT1,2 | (167/4) | 2.55 (0.34-18.65) | 0.36 | ||
pN (+/−) | (128/43) | 2.96 (1.43-6.14) | 0.0036* | 3.01 (1.37-6.59) | 0.006* |
R1,2/R0 | (70/101) | 2.12 (1.03-4.33) | 0.034* | 1.66 (0.78-3.54) | 0.19 |
Neoadjuvant therapy (+/−) | (74/97) | 1.02 (0.52-2.00) | 0.944 | ||
Adjuvant chemotherapy (+/−) | (146/25) | 0.42 (0.13-1.31) | 0.11 | ||
Stromal C4BPA (Low/High) | (75/96) | 2.50 (1.22-5.10) | 0.0096* | 2.54 (1.18-5.48) | 0.017* |
Stromal CD40 (Low/High) | (82/89) | 1.05 (0.54-2.05) | 0.86 | ||
CD8 expression (Low/High) | (77/94) | 2.06 (1.02-4.13) | 0.037* | 1.67 (0.80-3.50) | 0.16 |